IT should be notified now!

Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Donate to SABA Capital Campaign
Portal Access Behavior Analysis Training Directory Contact the Hotline View Frequently Asked Question
ABAI Facebook Page Follow us on Twitter LinkedIn LinkedIn
  • BPN: Behavioral Pharmacology and Neuroscience

Substance Use and Addiction Conference; Washington DC; 2018

Program by Invited Events: Monday, November 19, 2018


Invited Paper Session #2
Basic Behavioral Processes: Delay Discounting
Monday, November 19, 2018
8:30 AM–11:00 AM
Independence Hall A
Area: BPN
Instruction Level: Basic
CE Instructor: Mark Galizio, Ph.D.
Chair: Mark Galizio (University of North Carolina Wilmington)
Discussant: Leonard Green (Washington University)
Experimental Manipulations of Delay Discounting
GREGORY J. MADDEN (Utah State University)
Gregory J. Madden received his Ph.D. from West Virginia University and currently holds the position of professor at Utah State University, having previously held faculty positions at the University of Kansas and the University of Wisconsin–Eau Claire. Dr. Madden’s program of research has been aimed at understanding the basic mechanisms of reinforcement in humans and other animals, a topic of broad conceptual and applied significance in the field of psychology. He is an internationally known researcher in the field of behavioral economics, with special emphases on impulsive choice in gambling and drug addiction. Collectively, his work has merited more than $3 million of federal funding, and his peer-reviewed papers have been cited more than 3,500 times. Since 2010 he has been active in translational efforts, particularly in applications of behavioral economics to influencing childhood dietary decision-making. Dr. Madden has held several key editorial positions, and has served in leadership roles in professional societies and organizations, including the Executive Council of ABAI, Division 25 (Behavior Analysis) of the American Psychological Association (APA), and the Society for the Experimental Analysis of Behavior (SEAB). Especially noteworthy was his appointment as editor in chief of the Journal of the Experimental Analysis of Behavior. Dr. Madden has also co-edited two important and influential books, Impulsivity: The Behavioral and Neurological Science of Discounting and the APA Handbook of Behavior Analysis, Volumes I and II, both published by APA.
Abstract: Many behaviors posing significant risks to public health are characterized by repeated decisions to forego better long-term outcomes for immediate temptations. This steep discounting of delayed outcomes is correlated with addictions (e.g., substance abuse, obesity) and impactful behaviors such as seatbelt use and early sexual activity. As evidence accumulates that steep delay discounting plays a causal role in these maladaptive behaviors, researchers have begun identifying experimental methods for reducing discounting. This presentation will provide a systematic review of this literature, highlighting successes and areas in which further research is needed.
Delay Discounting and Genetics of Impulsivity
SUZANNE H. MITCHELL (Oregon Health & Science University)
Suzanne H. Mitchell, Ph.D., is a Professor at Oregon Health & Science University (OHSU) in the Department of Behavioral Neuroscience, with secondary appointments in Psychiatry and in the Oregon Institute for Occupational health Science. She obtained her B.Sc. and M.Sc. degrees at the University of Hull, England and her Ph.D. at SUNY-Stony Brook, USA. Her dissertation focused on the economics of foraging behavior of rats, examining the role of the energetic costs and benefits in feeding. Her committee was chaired by Howard Rachlin, whose influence made her sensitive to the role of temporal costs as well as energetic costs in determining the value of food rewards. During a post-doctoral fellowship at the University of Chicago, Dr. Mitchell worked with Harriet de Wit, Ph.D. using behavioral economics as an explanation for use of alcohol, nicotine/cigarettes, and amphetamine in humans. During that time she also began collaborating with Jerry Richards, Ph.D. on delay discounting studies with rats. Following her postdoctoral work, Dr. Mitchell was an assistant professor at the University of New Hampshire, where she continued to explore recreational drug use using behavioral economic models. She moved her lab to OHSU in 2001 from the University of New Hampshire to devote more time to research, particularly looking into why drug users tend to be more impulsive than non-drug users using human and animal models. Most recently she has returned to her earlier interests in energetic costs and her research has increased its scope to include effort-related decision-making in clinical populations. She has received funding from various NIH institutes (NHLBI, NIAAA, NIDA and NIH), has served on several study sections as a member and as an ad hoc participant, and has received awards for education and mentoring.
Abstract: High levels of impulsivity (delay discounting [DD], relative preference for smaller but immediate rewards over larger but delayed rewards) are associated with various psychopathologies including alcohol use disorder. Data indicate that there are genetic influences on DD and on the development of alcohol use disorder, but the genetic relationships amongst DD and alcohol consumption and other heritable features of alcohol response are unclear. This presentation will describe several techniques used to examine the role of genetics in behavior in animal models and a series of studies using them to examine the genetically-based co-relationships between excessive alcohol use and steep delay discounting. In these studies, male mice were exposed to the adjusting amount procedure (Richards et al. 1997, J Exp Anal Behav, 67, 353-366). This procedures requires mice to choose between a small, immediate sucrose-solution reward and a larger sucrose-solution reward that is delayed 0, 2, 4, 8 or 12 s on different sessions. In one study, behavior for 11 inbred strains was assessed, and genetic correlations with ethanol-associated endophenotypes derived. Other studies assessed DD in lines selected for differing levels of ethanol withdrawal symptomatology or ethanol consumption, and correlations between DD and responses to passively administered ethanol in a heterogeneous mouse stock to identify novel phenotypic targets. Data suggest that DD has a heritable component in mice, and is genetically associated with chronic withdrawal and consumption, but that effect sizes are small. Implications for human alcohol use and delay discounting will be discussed and knowledge gaps identified.
Target Audience: Board certified behavior analysts; licensed psychologists; graduate students.
Learning Objectives: At the conclusion of the presentation, participants will be able to: (1) discuss the delay discounting process; (2) understand how delay discounting may underlie decisions leading to addictions; (3) list at least 3 interventions that have proven successful in reducing delay discounting; (4) describe two procedures used in basic research to demonstrate the role of genetics in behavior; (5) explain the difference between a genotype, phenotype, and endophenotype; (6) discuss the data indicating that an individual’s level of delay discounting can be classified as an endophenotype; (7) describe behavioral procedures to assess alcohol-related phenotypes in mice; (8) assess the genetic-basis of the relationship between delay discounting and the potential for alcohol abuse.
Invited Paper Session #3
Models of Addiction and Treatment
Monday, November 19, 2018
12:30 PM–3:00 PM
Independence Hall A
Area: BPN
Instruction Level: Intermediate
CE Instructor: Mark Galizio, Ph.D.
Chair: Mark Galizio (University of North Carolina Wilmington)
Discussant: Amy Odum (Utah State University)
Reinforcer Pathology: A Conceptual Model of Addiction
WARREN K. BICKEL (Addiction Recovery Research Center, Virginia Tech Carilion Research Institute )
Dr. Bickel joined the Virginia Tech Carilion Research Institute in 2011 and serves as Director for the Addiction Recovery Research Center and Co-Director of the Center for Transformative Research on Health Behaviors. He has appointments as professor in the Department of Psychology at Virginia Tech; professor in the Department of Psychiatry, Virginia Tech Carilion School of Medicine; and Virginia Tech Faculty of Health Sciences. In recognition of his extraordinary contributions to research and scholarship achievements, Dr. Bickel recently was awarded the Virginia Tech Carilion Behavioral Health Research Endowed Professorship. He received his Ph.D. in developmental and child psychology from the University of Kansas and completed post doctoral training at Johns Hopkins University School of Medicine. Dr. Bickel then joined the faculty at the Albert Einstein College of Medicine where he taught and led a research program. He next relocated to the University of Vermont where he became a Professor in the Departments of Psychiatry and Psychology and Interim-Chair of the Department of Psychiatry. While in Vermont, he contributed to the public debate about treating opioid-dependent individuals and was the Founding Director of the first methadone treatment program in the State of Vermont. Dr. Bickel’s next appointment was at the University of Arkansas for Medical Sciences (UAMS). While at UAMS, he held the Wilbur D. Mills Chair of Alcoholism and Drug Abuse Prevention and was the Director of the Center for Addiction Research. He also served as Director of the College of Public Health’s Center for the Study of Tobacco Addiction and was the Associate Director of the Psychiatric Research Institute. Dr. Bickel is an accomplished scholar and researcher whose accolades include being named a 2014 Fellow in the Academy of Behavioral Medicine Research; the 2012 Brady-Schuster Award for Outstanding Behavioral Science Research in Psychopharmacology and Substance Abuse, Division 28 of the American Psychological Association (APA); and the 2011 APA International Don Hake Translational Research Distinguished Contributions to Basic Research Award. In 2012, he was selected by the APA Science Directorate and Board of Scientific Affairs as a Distinguished Scientist Lecturer. Dr. Bickel was honored to be the recipient of the 2016 Nathan B. Eddy Award from the College on Problems of Drug Dependence. Additionally, he has received an NIH MERIT Award from NIDA and NIH has funded Dr. Bickel’s work continuously since 1987. He has served as President of CPDD, President of APA Division 28 - Psychopharmacology and Substance Abuse, and President of APA Division 50 - Society of Addiction Psychology. Dr. Bickel was Editor of the journal, Experimental and Clinical Psychopharmacology, has co-edited five books, and has published over 340 papers and chapters. Dr. Bickel’s work frequently is cited and receives national and international recognition.
Abstract: Reinforcer pathology, a recent development in the field of behavioral economics, specifies that (1) reinforcers are integrated over time, (2) that length of the window of integration can vary, and, in turn, (3) alter the valuation of different reinforcers. Short temporal windows of integration will tend to increase the value of intense, reliable and brief reinforcers such as drugs while leading to a decline in the value of reinforcers that are less intense, variable and accrue value over longer time frames such as prosocial reinforcers. Conversely, long temporal windows of integration should result in a reversal in the valuation of drug and prosocial reinforcers. Importantly, reinforcer pathology provides an understanding of the "anhedonia" that often occurs in the development of addiction and suggests a novel approach to treatment; namely, to increase the length of the temporal integration window. In this presentation, this model and data supporting it will be reviewed.
Self-Sustaining Treatments for Drug Addiction and Incubation of Craving Leading to Relapse
MARILYN CARROLL (University of Minnesota)
Dr. Marilyn Carroll received her BS in Psychology and BA in Pre-Law from Penn State University in 1968. After working in Washington DC for 3 years on government research projects with the Office of Economic Opportunity, she completed her Ph.D. in Psychobiology and Neuroscience from Florida State University from 1971–75 with Dr. James C. Smith as her mentor on a T32 Psychobiology training fellowship. From 1975–76 she taught Psychology and Statistics courses at Macalester College in St. Paul, and from 1976–1980 she conducted postdoctoral research at the University of Minnesota with Dr. Richard A. Meisch under a T31 training fellowship from NIDA on animal models of addiction using rats and rhesus monkeys. She continued on in the Psychiatry Department in Minnesota in 1980 as an Assistant Professor, Associate Professor, and since 1993 has been Professor in Psychiatry and Neuroscience, and adjunct Professor in Psychology. Dr. Carroll’s research interests have been focused on biological factors in drug addiction (Sex and hormonal, impulsivity, sweet preference, and stress) and behavioral economic factors. Currently she focuses on treatments for addiction that are sex-specific, sensitive to hormonal influences, novel, environmentally enriching, self-sustaining over long periods that cover craving during abstinence (e.g., exercise, vaccines), target underlying behaviors (anxiety, impulsivity), and combination therapies.
Abstract: The goal of my research is to model various forms of human drug addiction in animals, taking into account factors that increase or decrease addiction potential and severity such as sex, hormonal factors, impulsivity, sweet preference, and other genetic factors. My students, colleagues, and I have also developed self-sustaining treatments to reduce or eliminate incubation of craving and subsequent drug-seeking over long periods of time. My research has been involved in the development of novel methods of modeling drug addiction in rats and nonhuman primates, with self-administration of opioids, stimulants, alcohol, and with several routes of self-administration used by humans, such as intravenous, drinking (oral), and smoking. Behavioral economic methods and analyses of demand for drug self-administration and behavioral patterns have been compared in humans and nonhuman animals to better understand factors that increase and treatments that reduce demand for drugs. Recent work has focused on self-motivated novel treatments for drug addiction such offering concurrent, nondrug rewards like physical exercise that reduce initiation, acceleration of drug use, and prevent relapse. Self-motivated alternative behaviors, such as physical exercise, also reduce long-term drug craving. That is important because animal models indicate that craving continues for months after standard treatments end. Current studies are also extending these findings to prevention models and to models of binge eating and food addiction in animals.
Target Audience: Board certified behavior analysts; licensed psychologists; graduate students.
Learning Objectives: At the conclusion of the presentation, participants with be able to: (1) describe two procedures used in basic research to demonstrate the role of genetics in behavior; (2) explain the difference between a genotype, phenotype, and endophenotype; (3) discuss the data indicating that an individuals level of delay discounting can be classified as an endophenotype; (4) describe behavioral procedures to assess alcohol-related phenotypes in mice; (5) assess the genetic-basis of the relationship between delay discounting and the potential for alcohol abuse.
Invited Paper Session #4
Contingency Management for Drug Problems
Monday, November 19, 2018
3:30 PM–6:00 PM
Independence Hall A
Area: BPN
Instruction Level: Basic
CE Instructor: Mark Galizio, Ph.D.
Chair: Mark Galizio (University of North Carolina Wilmington)
Discussant: Maxine Stitzer (Behavioral Pharmacology Research Unit)
Contingency Management in the 21st Century: Technology and the Future
JESSE DALLERY (University of Florida)
Jesse is a Professor in the Department of Psychology at the University of Florida, a Licensed Psychologist in the state of Florida, and Deputy Director of the Treatment Development and Implementation Core at the Center for Technology and Behavioral Health at Dartmouth. Jesse received his Ph.D. in Clinical Psychology at Emory University, and completed a postdoctoral fellowship at the Johns Hopkins University School of Medicine in Behavioral Pharmacology. Jesse’s research focuses on integrating information technologies with behavioral interventions for cigarette smoking and other health-related behavior (e.g., physical activity, medication adherence). Jesse also conducts translational research on choice and decision making in the human laboratory, with a special emphasis on quantitative models of operant behavior. He has published over eighty articles in a diverse range of peer-reviewed journals, and he has received grant support from the National Institutes of Health and from the National Science Foundation. He is co-editor of the book Behavioral Health Care and Technology: Using Science-Based Innovations to Transform Practice. Jesse is a former Associate Editor for The Behavior Analyst and Behavioural Processes, and Special Topics Associate Editor (substance abuse) for the Journal of Applied Behavior Analysis. In 2014, Dr. Dallery was named a Teacher of the Year in the College of Liberal Arts and Sciences.
Abstract: Contingency management is one of the most efficacious interventions to promote drug abstinence. Traditionally, contingency management has been delivered in person so that clinicians can confirm drug abstinence and provide access to additional therapeutic services. Now, new technologies not only permit remote confirmation of abstinence, but also remote delivery of incentives. I will discuss several technology-based tools to assess substance use, and new ways to deliver contingency management to promote tobacco and alcohol abstinence. These new tools have the potential to dramatically increase access while maintaining high levels of treatment fidelity. They also allow new ways of arranging contingencies that harness natural, online communities and consequences. Overall, there are unprecedented opportunities to link technology with contingency management to promote drug abstinence.
An Overview of Contingency Management Interventions in Substance Abuse Treatment: With Whom is it Effective and Where is it Applied?
CARLA J. RASH (UConn Health)
Carla Rash earned a Ph.D. in clinical psychology from Louisiana State University in 2007. She is currently an assistant professor in the Department of Medicine at UConn Health. Her research interests focus on extending and evaluating addictions treatments, including contingency management interventions, in underserved and health disparity populations. Her work is funded by the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, and by a career development award from the Connecticut Institute for Clinical and Translational Science.
Abstract: Contingency management (CM) interventions are efficacious options for substance abuse treatments, but they are rarely implemented in clinical, non-research settings. In this presentation, we briefly review the evidence support for CM and introduce prize-based CM. We will highlight work that supports CM’s generalizability across diverse patient characteristics and settings. We will conclude with a discussion of potential implementation barriers and examples of real-world implementation efforts.
Target Audience: Board certified behavior analysts; licensed psychologists; graduate students.
Learning Objectives: At the conclusion of the presentation, participants will be able to: (1) summarize the efficacy literature related to CM interventions for the treatment of substance use disorders; (2) describe the populations and settings appropriate for CM interventions; (3) list potential barriers to dissemination; (4) describe real-world implementation efforts; (5) describe how sensors can be used to obtain objective evidence of at least two different drugs of abuse; (6) describe how information technology can be used to deliver immediate incentives for abstinence; (7) describe how social networks have been used to promote smoking cessation using information technology.



Back to Top
Modifed by Eddie Soh